128 related articles for article (PubMed ID: 38369638)
21. 78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients.
Choong ES; Hruby G; Yang J; Kwong C; Patanjali N
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e356-e363. PubMed ID: 27863019
[TBL] [Abstract][Full Text] [Related]
22. Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.
Maulik S; Arunsingh M; Arun B; Prasath S; Mallick I
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e52-e60. PubMed ID: 34456107
[TBL] [Abstract][Full Text] [Related]
23. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
[TBL] [Abstract][Full Text] [Related]
24. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients.
Napieralska A; Majewski W; Kulik R; Głowacki G; Miszczyk L
Radiat Oncol; 2018 Nov; 13(1):235. PubMed ID: 30482212
[TBL] [Abstract][Full Text] [Related]
25. Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.
Tomita N; Soga N; Ogura Y; Furusawa J; Tanaka H; Koide Y; Tachibana H; Kodira T
Asia Pac J Clin Oncol; 2019 Feb; 15(1):18-25. PubMed ID: 30411504
[TBL] [Abstract][Full Text] [Related]
26. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.
Deville C; Both S; Bui V; Hwang WT; Tan KS; Schaer M; Tochner Z; Vapiwala N
Radiat Oncol; 2012 May; 7():76. PubMed ID: 22621764
[TBL] [Abstract][Full Text] [Related]
27. A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer.
Rice SR; Olexa G; Hussain A; Mannuel H; Naslund MJ; Amin P; Kwok Y
Am J Clin Oncol; 2019 Mar; 42(3):285-291. PubMed ID: 30676332
[TBL] [Abstract][Full Text] [Related]
28. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
29. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
Glicksman RM; Loblaw A; Morton G; Vesprini D; Szumacher E; Chung HT; Chu W; Liu SK; Tseng CL; Correa R; Deabreu A; Mamedov A; Zhang L; Cheung P
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):100-109. PubMed ID: 37979707
[TBL] [Abstract][Full Text] [Related]
30. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
[TBL] [Abstract][Full Text] [Related]
31. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China.
Zhong QZ; Xia X; Gao H; Xu YG; Zhao T; Wu QH; Wang D; Lin HL; Sha XY; Liu M; Li GF
Aging (Albany NY); 2021 Feb; 13(5):6936-6944. PubMed ID: 33653964
[TBL] [Abstract][Full Text] [Related]
33. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.
Niazi T; Nabid A; Malagon T; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Tsui JMG; Mohiuddin M
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):52-62. PubMed ID: 37224928
[TBL] [Abstract][Full Text] [Related]
35. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
36. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
37. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT.
Guckenberger M; Lawrenz I; Flentje M
Strahlenther Onkol; 2014 Jan; 190(1):48-53. PubMed ID: 24196279
[TBL] [Abstract][Full Text] [Related]
38. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
39. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
40. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]